+ 7 (495) 684-04-00

Tag: Medtech

Wearable Medtech

couch legs
An analyst has picked up on a beaten down medtech company in an underserved market that is technically set up to run if earnings come out with good news.

Back to Science

We review a name we had good luck with last year. As medtech has gone nowhere with the Delta variant keeping elective procedures to a minimum, company management feels things are changing for the better.
To access this post, you must purchase Subscription Plan – AVC Pro.

Pre-Earning Frowns

smiley and frowns
An investment bank has moderated its generally bullish view on Q3 earnings expectations for a Wall Street sweetheart.
To access this post, you must purchase Subscription Plan – AVC Pro.

Medtech: Reimbursement Price Noise

Medtech header
After July rumblings of increased fees and lack of reimbursements for this medtech company's products, a recent survey shows uptake is growing above expectations.
To access this post, you must purchase Subscription Plan – AVC Pro.

Medtech Low Risk Trade

medtech
Legislation changes and a tie up with another major medtech innovator help propel this company's product into every operating room.
To access this post, you must purchase Subscription Plan – AVC Pro.

Friday Investment Talk: Semiconductors, Inflation, Bonds and Biotech

Friday Investment Talk Feb19
The global semiconductor shortage calls for capital investments. Commodity inflation is here. CPIs are low still, but long bonds sell off. Biotech is a sweet spot.

Stock Commentary

Sphere
We update some notes on 20 stocks that we have covered on our blog and Telegram channel. Many present very compelling opportunities right now.
To access this post, you must purchase Subscription Plan – AVC Pro.

Trade Idea: Rebound from Overreaction

Self Diagnostics
A high flying medical diagnostics company has investors scared of falling revenue after COVID vaccines become available. The reaction was a strong sell off and now the stock is back on track towards its all time highs.
To access this post, you must purchase Subscription Plan – AVC Pro.

Stock Research: A Dialysis Play

dialysys
U.S., estimated annual dialysis spending approximates $74B and the main market players have not changed for 30 years. A new medtech company is set to disrupt the market.
To access this post, you must purchase Subscription Plan – AVC Pro.

Stock Research: Recent Medtech IPO

We are following up on a recent IPO idea published on our telegram channel. This Medtech company looks towards a post COVID expansion in Europe and Asia.
To access this post, you must purchase Subscription Plan – AVC Pro.

For Whom

Our Expertise

Our Solutions

This information is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not correspond to your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or transaction matches your interests, investment objectives, investment horizon and acceptable risk level. AVC Adisvory, Inc. and its affiliates are not liable for possible losses in case of making transactions or investing in the financial instruments mentioned in this information, and do not recommend using this information as the only source of information when making an investment decision.

Twitter Facebook Linkedin-in Youtube Telegram-plane
Scroll to Top